Our results suggest that, AMs in vitro model could be a novel cytological tool for studies on paraquat poisoning and therapy regimens.
The mainstays of treatment are removal from the source of lead and, for people who have significantly high blood lead levels or who have symptoms of poisoning, chelation therapy.
For acute inorganic mercury poisoning chelation therapy can be done with DMSA, 2,3-dimercapto-1-propanesulfonic acid (DMPS), D-penicillamine (DPCN), or dimercaprol (BAL) [ 135].
In the overall long-term management of lead poisoning, chelation therapy can have short-term benefits; however, these benefits must be accompanied by drastic reduction in environmental exposure to lead if therapy is to have any long-term benefit.
We surveyed 23 clinicians, who had different levels of exposure to seeing AChE levels in OP poisoned patients, on a) knowledge of OP poisoning and biomarker interpretation, b) attitudes towards AChE in guiding poison management, oxime therapy and discharge decisions, and c) practices of ordering AChE in poisoning scenarios.
In severe poisoning, hyperbaric oxygen therapy is regarded as the therapy of choice [ 11].
For the long-term sequelae of acute CO poisoning, only symptomatic therapy is available.
For example, the Guys and St. Thomas Medical Toxicology Clinic in the UK saw many tens of patients with significant lead poisoning requiring chelation therapy in South London from 1998 2006.
Finally, use of the model to explore situations with limited data is illustrated by simulating the kinetics and disposition of Pb during acute Pb poisoning and chelation therapy in a child.
These can include ear infections and a number of ear conditions, head injuries, food poisoning and radiation therapy.
